SG11201808246SA - Methods for treating and preventing c. difficile infection - Google Patents

Methods for treating and preventing c. difficile infection

Info

Publication number
SG11201808246SA
SG11201808246SA SG11201808246SA SG11201808246SA SG11201808246SA SG 11201808246S A SG11201808246S A SG 11201808246SA SG 11201808246S A SG11201808246S A SG 11201808246SA SG 11201808246S A SG11201808246S A SG 11201808246SA SG 11201808246S A SG11201808246S A SG 11201808246SA
Authority
SG
Singapore
Prior art keywords
treating
preventing
methods
difficile infection
difficile
Prior art date
Application number
SG11201808246SA
Other languages
English (en)
Inventor
S Tanaka
Michael Draper
Original Assignee
Paratek Pharm Innc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharm Innc filed Critical Paratek Pharm Innc
Publication of SG11201808246SA publication Critical patent/SG11201808246SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201808246SA 2016-03-24 2017-03-24 Methods for treating and preventing c. difficile infection SG11201808246SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662312996P 2016-03-24 2016-03-24
US201662320053P 2016-04-08 2016-04-08
PCT/US2017/023958 WO2017165729A1 (en) 2016-03-24 2017-03-24 Methods for treating and preventing c. difficile infection

Publications (1)

Publication Number Publication Date
SG11201808246SA true SG11201808246SA (en) 2018-10-30

Family

ID=59900751

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201808246SA SG11201808246SA (en) 2016-03-24 2017-03-24 Methods for treating and preventing c. difficile infection
SG10201913559VA SG10201913559VA (en) 2016-03-24 2017-03-24 Methods for treating and preventing c. difficile infection

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913559VA SG10201913559VA (en) 2016-03-24 2017-03-24 Methods for treating and preventing c. difficile infection

Country Status (13)

Country Link
US (3) US20170319603A1 (OSRAM)
EP (1) EP3432891A4 (OSRAM)
JP (3) JP7458706B2 (OSRAM)
CN (2) CN119454720A (OSRAM)
AU (3) AU2017238644B2 (OSRAM)
BR (2) BR112018069303A2 (OSRAM)
CA (1) CA3018872A1 (OSRAM)
MX (2) MX2018011413A (OSRAM)
MY (1) MY197627A (OSRAM)
PH (1) PH12018502020A1 (OSRAM)
RU (1) RU2751509C1 (OSRAM)
SG (2) SG11201808246SA (OSRAM)
WO (1) WO2017165729A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119454720A (zh) * 2016-03-24 2025-02-18 帕拉特克Spv2有限责任公司 用于治疗和预防艰难梭菌感染的方法
TW202206081A (zh) * 2016-08-03 2022-02-16 美商派瑞泰Ｓｐｖ２有限公司 ９—胺甲基米諾四環素化合物及其用途
RU2019113715A (ru) * 2016-11-01 2020-12-03 Паратек Фармасьютикалс, Инк. 9-аминометилминоциклиновые соединения и их применение для лечениия внебольничной бактериальной пневмонии(вбп)
JP7110562B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP7110563B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP7110560B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP2019136429A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
JP2019136430A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
JP2019136431A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
BR112021004057A2 (pt) * 2018-09-04 2021-05-25 Paratek Pharmaceuticals, Inc. métodos de tratar ou prevenir uma infecção micobacteriana, de tratar ou prevenir, de controlar ou reduzir o avanço, severidade ou efeitos de uma doença micobacteriana, tuberculose, lepra, bronquiectasia, doença pulmonar cavitária, linfadenite, uma doença de tecido mole, granuloma de aquário, úlcera de buruli, uma doença ocular e doença óssea em um indivíduo em necessidade dos mesmos, e, métodos de tratar um indivíduo com uma doença pulmonar e de tratar um indivíduo com uma condição imunossuprimida.
US11730776B2 (en) * 2018-10-10 2023-08-22 Nutri Co., Ltd. Preventive and/or therapeutic agent for clostridium difficile infection
WO2021252876A1 (en) * 2020-06-11 2021-12-16 Paratek Pharmaceuticals, Inc. Crystalline forms of omadacycline, methods of synthesis thereof and methods of use thereof
PT117254B (pt) 2021-05-26 2024-04-18 Hovione Farm S A Método de síntese de compostos 9-aminometil tetraciclinas
JP2023105293A (ja) * 2022-07-21 2023-07-28 株式会社三洋物産 遊技機
JP2023105292A (ja) * 2022-07-21 2023-07-28 株式会社三洋物産 遊技機

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2324392A (en) * 1991-07-24 1993-02-23 Procter & Gamble Company, The Antimicrobial treatment methods and compositions
EA201000496A1 (ru) * 2000-07-07 2010-10-29 Трастис Оф Тафтс Коллидж Замещенное соединение миноциклина, способ получения замещенных соединений миноциклина (варианты)
US7553828B2 (en) * 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
EP2332549A1 (en) * 2001-07-13 2011-06-15 Paratek Pharmaceuticals, Inc. Novel tetracyclines and their use in medicine
AU2006331685A1 (en) * 2005-12-22 2007-07-05 Wyeth Methods of treating gastrointestinal tract infections with tigecycline
WO2007087416A2 (en) * 2006-01-24 2007-08-02 Paratek Pharaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
TW202216656A (zh) * 2008-05-19 2022-05-01 美商Ｐｒｔｋ Ｓｐｖ２公司 四環素化合物之甲苯磺酸鹽及同素異形體
EP2396029A4 (en) * 2009-02-11 2012-08-08 Cedars Sinai Medical Center ANTIBIOTIC THERAPY FOR REDUCING THE PROBABILITY OF THE DEVELOPMENT OF POST-INFECTIOUS REIZDARY SYNDROME
CN102947334B (zh) * 2010-04-15 2017-12-26 普罗杰尼克制药股份有限公司 用于治疗艰难梭菌相关感染和疾病的抗体
WO2012050826A1 (en) * 2010-09-29 2012-04-19 St. Jude Children's Research Hostpital Methods for treating clostridium difficile infections
WO2012065028A2 (en) * 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
JP2016509003A (ja) * 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 組成物および方法
US20140274800A1 (en) * 2013-03-13 2014-09-18 Procarta Biosystems Ltd. Transcription factor decoys for the treatment and prevention of infections caused by bacteria including clostridium difficile
CN119454720A (zh) * 2016-03-24 2025-02-18 帕拉特克Spv2有限责任公司 用于治疗和预防艰难梭菌感染的方法

Also Published As

Publication number Publication date
AU2017238644B2 (en) 2022-12-15
EP3432891A1 (en) 2019-01-30
JP2022115985A (ja) 2022-08-09
US20200281948A1 (en) 2020-09-10
BR122024000249A2 (pt) 2024-02-27
US20170319603A1 (en) 2017-11-09
AU2017238644A1 (en) 2018-10-25
EP3432891A4 (en) 2019-10-30
US20250049819A1 (en) 2025-02-13
AU2025202020A1 (en) 2025-04-10
CA3018872A1 (en) 2017-09-28
AU2023200798A1 (en) 2023-03-09
MY197627A (en) 2023-06-29
CN109152789A (zh) 2019-01-04
WO2017165729A1 (en) 2017-09-28
MX2023004969A (es) 2023-05-24
CN119454720A (zh) 2025-02-18
BR112018069303A2 (pt) 2019-01-22
RU2751509C1 (ru) 2021-07-14
JP2019509318A (ja) 2019-04-04
PH12018502020A1 (en) 2019-07-15
JP7458706B2 (ja) 2024-04-01
SG10201913559VA (en) 2020-02-27
JP2024023187A (ja) 2024-02-21
MX2018011413A (es) 2019-01-10

Similar Documents

Publication Publication Date Title
IL283779A (en) Systems and methods for preventing, alleviating and/or treating dementia
SG11201808246SA (en) Methods for treating and preventing c. difficile infection
IL274040A (en) Methods for treating hepatitis B infection
IL269371A (en) Treatment methods
EP3151797A4 (en) Methods and devices for treating the skin
EP3107642A4 (en) Systems and methods for treating blood
IL254596B (en) A method for operating a reverse osmosis membrane treatment system and a reverse osmosis membrane treatment system
ZA201700416B (en) Methods for treating or preventing ophthalmological conditions
GB201608885D0 (en) Treatment
IL271728A (en) Materials, uses and treatment methods
IL291266A (en) Preparations and methods for treating infections
IL252197A0 (en) A method for treating, preventing or reducing the risk of skin infection
ZA201907283B (en) Compositions, devices and methods for treating autism
EP3283103A4 (en) Methods for treating clostridium difficile infection and associated disease
GB201402909D0 (en) Treating infection
EP3139744A4 (en) Methods and compositions for treating and preventing tinnitus
ZA201904328B (en) Composition, application thereof and treatment method
PL3481194T3 (pl) Wodne kompozycje do zaprawiania nasion, zaprawione nimi nasiona i sposoby zaprawiania nasion
EP3258958A4 (en) Compositions and methods for preventing and treating rhinovirus infections
HK40099982A (zh) 用於治疗hbv的手段和方法
HK40003650A (en) Methods for treating and preventing c. difficile infection
EP3490369A4 (en) WATER TANK FOR DOMESTIC ANIMALS, TREATMENT AND RELATED METHODS
HK1262014A1 (en) Methods for preventing and treating pneumocystis infections
HK1229638A1 (en) Methods and compositions for treating and preventing tinnitus
IL252399A0 (en) Systems and methods for water repellent treatment in protective fabrics, and protective fabrics produced using them